Seqens at the High Level Event organised by the EU Commission


SEQENS represented EFCG at the high-level structured dialogue organized by the European Commission to build a resilient pharma industry in Europe in accordance with the EU Pharmaceutical Roadmap

Building the future pharma industry

At the European Commission’s kick-off meeting of the structured dialogue that took place today with  public authorities and patient nongovernmental organisations, the European Fine Chemicals Group (EFCG), the European Federation of Pharmaceutical Industries and Associations (EFPIA) and Medicines for Europe pledged to work hand in hand in the coming months to ensure the success of Europe’s ambitious Pharmaceutical strategy.

As EFCG, SEQENS considers that regaining Europe’s health autonomy will greatly depend on our ability to maintain and develop its existing industrial base as well as invest in clean, innovative and sustainable technologies. We are convinced that, to build a robust pharmaceutical synthesis industry in Europe, providing affordable, accessible and available medicines to all its citizens, we need to:

  • support the existing European manufacturers of APIs and intermediates in the on-shoring of technologies that will guarantee the supply of the essential medicines;
  • level the playing field with other world regions to ensure that criteria as important as the security of supply, process safety and respect for the environment are also considered for the purchase of products, and
  • accelerate sustainable Research, Development and industrialization of innovative and green technologies.

As an integrated player in the production of APIs and intermediates, SEQENS is fully committed to taking on this challenge and the group has already decided to accelerate the development and production on its industrial facilities of critical molecules along the value chain of essential drugs.

With the support of the France Relance program, SEQENS plans to invest €65 million in capacity increase and implementation of new technologies on five of its APIs and pharmaceutical intermediates production sites. Relying on cutting-edge technologies and processes developed in the SEQENS’Lab, the new units will enable competitive and sustainable production of critical molecules on our production facilities while guaranteeing a high level of performance, particularly in terms of safety and environment.

Seqens welcomes the launch of a structured dialogue at European level to improve the resilience of value chains that are absolutely essential for the European health security and the health of our fellow citizens. The future of our industry will depend on the ability of our pharmaceutical synthesis companies to innovate and boost productive investments. SEQENS is ready to take up the challenge while relying on innovation, R&D and the skills of our teams on our production sites! “says Pierre Luzeau, SEQENS’ President.


SEQENS’ predisent